NFE2L2 and amyotrophic lateral sclerosis: The repurposing of the already FDA-approved Nrf2 activator, fingolimod phosphate, which is already used for the treatment of multiply sclerosis, and showed efficacy on ALS in vivo models, could serve as an additional therapeutic approach [81].